Healthcare · NIFTY 500
Natco Pharma Limited
₹828.65 +18.20 (+2.25%) Updated 16 Nov, 8:44 pm IST
Today
- Open
- ₹825.00
- Prev close
- ₹810.45
- Day high
- ₹881.80
- Day low
- ₹809.15
- Volume
- 44.91 L
- Value traded
- ₹376.26 Cr
- Upper circuit
- ₹972.50
- Lower circuit
- ₹648.40
- 52W high
- ₹1,226.80
- 52W low
- ₹773.60
- 1 month
- +3.25%
- 6 months
- -30.47%
Ratios
Key numbers
Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.
Quarterly results
Results for each quarter
Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.
Revenue and net profit
Revenue · QoQ (vs last quarter)
Revenue · YoY (vs a year ago)
Net profit · QoQ (vs last quarter)
Net profit · YoY (vs a year ago)
EPS (₹) · YoY (vs a year ago)
| ₹ Cr | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 759 | 1,068 | 1,363 | 1,371 | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 | 735 | 967 |
| Other income | 37.0 | 42.0 | 48.1 | 63.8 | 176 | 66.3 | 61.7 | 100 | 58.1 | 77.8 | 59.2 | 52.1 |
| Total income | 796 | 1,110 | 1,411 | 1,435 | 651 | 1,287 | 1,391 | 1,463 | 705 | 817 | 794 | 1,019 |
| Raw material | 92.2 | 128 | 151 | 143 | 72.7 | 169 | 181 | 175 | 135 | 103 | 158 | 172 |
| Purchases | 36.7 | 31.1 | 32.5 | 53.7 | 39.1 | 40.8 | 37.3 | 72.6 | 55.8 | 37.5 | 27.8 | 81.8 |
| Employee cost | 122 | 143 | 142 | 152 | 142 | 159 | 169 | 200 | 159 | 159 | 179 | 204 |
| Other expenses | 206 | 286 | 236 | 238 | 212 | 264 | 356 | 414 | 196 | 298 | 222 | 323 |
| Total expenses | 539 | 633 | 607 | 617 | 487 | 781 | 819 | 849 | 544 | 673 | 609 | 776 |
| Operating profit | 268 | 497 | 805 | 804 | 38.8 | 548 | 571 | 579 | 159 | 128 | 187 | 258 |
| OPM % | 35.3% | 46.6% | 59.1% | 58.7% | 8.2% | 44.9% | 43.0% | 42.5% | 24.5% | 17.3% | 25.4% | 26.7% |
| Finance cost | 4.6 | 6.2 | 5.2 | 4.1 | 4.4 | 10.2 | 3.2 | 13.1 | 9.5 | 10.9 | 13.0 | 17.6 |
| Depreciation | 44.2 | 55.5 | 44.1 | 45.8 | 47.0 | 98.3 | 57.6 | 52.4 | 46.2 | 50.4 | 47.1 | 49.2 |
| Profit before tax | 256 | 478 | 804 | 818 | 164 | 506 | 572 | 614 | 161 | 144 | 186 | 243 |
| Tax | 43.6 | 91.3 | 135 | 142 | 31.3 | 99.9 | 91.6 | 95.8 | 20.7 | -89.2 | 63.4 | 69.8 |
| Net profit | 213 | 386 | 669 | 677 | 132 | 406 | 480 | 518 | 151 | 269 | 207 | 203 |
| Profit to shareholders | 213 | 386 | 669 | 677 | 133 | 407 | 481 | 518 | 152 | 268 | 207 | 203 |
| EPS (₹) | 11.88 | 21.56 | 37.32 | 37.81 | 7.43 | 22.70 | 26.84 | 28.94 | 8.46 | 14.96 | 11.53 | 11.31 |
Profit & loss
Results for each year
8 financial years (April to March), consolidated, ₹ crore.
Sales, operating profit and net profit
Revenue · YoY (vs a year ago)
Net profit · YoY (vs a year ago)
| ₹ Cr | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,095 | 1,915 | 2,052 | 1,945 | 2,707 | 3,999 | 4,430 | 4,078 |
| Other income | 130 | 107 | 104 | 99.0 | 105 | 128 | 355 | 298 |
| Total expenses | 1,400 | 1,454 | 1,576 | 1,842 | 1,950 | 2,453 | 2,493 | 2,885 |
| Employee cost | 356 | 375 | 415 | 445 | 487 | 525 | 595 | 687 |
| Operating profit | 795 | 583 | 606 | 264 | 936 | 1,751 | 2,196 | 1,437 |
| OPM % | 37.9% | 30.4% | 29.5% | 13.5% | 34.6% | 43.8% | 49.6% | 35.2% |
| Finance cost | 19.3 | 21.5 | 13.3 | 17.7 | 14.5 | 19.2 | 23.9 | 36.7 |
| Depreciation | 81.0 | 99.8 | 117 | 143 | 164 | 187 | 235 | 207 |
| Profit before tax | 825 | 569 | 580 | 202 | 862 | 1,674 | 2,291 | 1,491 |
| Tax | 182 | 111 | 137 | 32.2 | 147 | 285 | 408 | 119 |
| Tax rate % | 22.1% | 19.4% | 23.7% | 15.9% | 17.0% | 17.0% | 17.8% | 8.0% |
| Net profit | 642 | 458 | 442 | 170 | 715 | 1,388 | 1,883 | 1,419 |
| Profit to shareholders | 644 | 461 | 441 | 170 | 715 | 1,388 | 1,885 | 1,419 |
| Net margin % | 30.8% | 24.1% | 21.5% | 8.7% | 26.4% | 34.7% | 42.6% | 34.8% |
| EPS (₹) | 34.87 | 25.26 | 24.16 | 9.32 | 39.18 | 77.34 | 105.26 | 79.20 |
Balance sheet
Assets and debt
At each year end (and the latest half year), ₹ crore.
Equity, debt and assets
Shareholders' equity · YoY (vs a year ago)
| ₹ Cr | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Sep 26 |
|---|---|---|---|---|---|
| Shareholders' equity | 4,874 | 5,853 | 7,607 | 9,221 | 9,765 |
| Long-term borrowings | 0.0 | 0.0 | 0.0 | 100 | 0.0 |
| Short-term borrowings | 165 | 363 | 273 | 606 | 1,027 |
| Total borrowings | 165 | 363 | 273 | 706 | 1,027 |
| Current liabilities | 683 | 973 | 944 | 1,681 | 1,950 |
| Fixed assets (PPE) | 2,239 | 2,298 | 2,432 | 2,545 | 2,596 |
| Inventories | 743 | 701 | 766 | 909 | 1,006 |
| Trade receivables | 856 | 1,189 | 1,247 | 881 | 803 |
| Cash & equivalents | 132 | 70.4 | 120 | 199 | 139 |
| Current assets | 3,000 | 4,024 | 5,270 | 5,052 | 4,235 |
| Total assets | 5,657 | 6,906 | 8,631 | 11,074 | 11,799 |
| Debt / equity | 0.03 | 0.06 | 0.04 | 0.08 | 0.11 |
Cash flow
Cash coming in and going out
For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.
Operating, investing and financing cash
Operations · YoY (vs a year ago)
| ₹ Cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 46.5 | 849 | 1,212 | 1,697 | 1,768 |
| Cash from investing | -5.3 | -477 | -1,033 | -1,415 | -2,143 |
| Cash from financing | 34.8 | -363 | -247 | -211 | 298 |
| Spent on fixed assets | -233 | -146 | -339 | -401 | -388 |
| Free cash flow | -186 | 703 | 872 | 1,296 | 1,380 |
| Net cash flow | 76.0 | 9.0 | -68.0 | 71.6 | -77.1 |
Shareholding
Who holds the shares
Promoter and public holding at each quarter end, as filed with NSE.
Holding over time
Latest (23 Oct 2026)
- Promoter & group
- 46.22%
- Public (FIIs, mutual funds, retail…)
- 53.78%
- Promoter change, last quarter
- -3.17 pts
Dividends & news
Latest dividends and announcements
Dividends & corporate actions
- Interim Dividend - Rs 1.25 Per Share
- Rights 2:21 @ Premium Rs 748/-
- Interim Dividend - Rs 1.50 Per Share
- Interim Dividend - Rs 1.50 Per Share
- Interim Dividend - Rs 1.50 Per Share
- Interim Dividend - Rs 2 Per Share
- Interim Dividend - Rs 1.50 Per Share
- Interim Dividend - Rs 1.50 Per Share
Board meetings
- the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Dividend.
- the financial results for the period ended September 30, 2026 and dividend
- Fund raising.
- to consider, discuss and decide various matters in connection with the Rights Issue, including the specific terms of the Rights Issue, such as the de…
- Fund raising.
Filings with NSE
- Analysts/Institutional Investor Meet/Con. Call Updates
- Copy of Newspaper Publication
- Analysts/Institutional Investor Meet/Con. Call Updates
- Investor Presentation
- Record Date
- Outcome of Board Meeting
- Analysts/Institutional Investor Meet/Con. Call Updates
Latest news
Natco Pharma Ltd. Rights Issue: Price, Record Date, Entitlement Ratio And Key DetailsICICI Direct · 9 Oct, 12:30 pmBuy Natco Pharma: target of Rs 1065: ICICI SecuritiesMoneycontrol.com · 16 Nov, 12:52 pmNifty 500: Belrise jumps 10% on profit growth, Kaynes Technology plunges 17% to 52-wk low on Q2 resultsCNBC TV18 · 16 Nov, 9:56 amNatco Pharma Plans ₹1,279 Cr Rights Issue at ₹750HDFC Sky · 25 Sep, 12:30 pmNatco Pharma Q2 results: Net profit declines 60.8% to ₹202.6 croreBusiness Standard · 13 Nov, 3:53 pmNatco Pharma’s board approves rights issue worth ₹1,279 crore; check issue price, record date and moreUpstox · 25 Sep, 12:30 pmNatco Pharma Q2FY27 Results: Net profit falls 61% YoY to ₹203 crorescanx.trade · 13 Nov, 2:27 pmNatco Pharma Q2 Net Profit Plunges 60.8% to Rs 202.6 CrRediff MoneyWiz · 13 Nov, 3:45 pmAbout
About Natco Pharma Limited
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations, active pharmaceutical ingredients and agrochemical products. It is a major producer of branded oncology medicines cardiology, diabetology and other pharma specialty drugs at affordable prices.
From Wikipedia (CC BY-SA 4.0).
Company details
- Company name
- Natco Pharma Limited
- NSE symbol
- NATCOPHARM
- BSE scrip code
- 524816
- ISIN
- INE987B01026
- Listed on
- NSE, BSE
- Series
- EQ (normal equity)
- Listed on NSE since
- 27 Dec 1995
- Face value
- ₹2 per share
- Market lot
- 1 share
- Shares issued
- 17.90 crore
- Index
- NIFTY 500
- Sector (NSE)
- Healthcare
- Industry
- Pharmaceuticals: Major
- Chair
- Venkaiah Chowdary Nannapaneni
- Headquarters
- Hyderabad
- Registered address
- NATCO HOUSE ROAD NO 2 BANJARA HILLS HYDERABAD
- Founded
- 1981
- Employees
- 5,060
- Financial year
- April to March
- Results basis
- Consolidated
- Website
- natcopharma.co.in
Peers
Other Healthcare stocks
-
LAURUSLABSLaurus Labs ₹2,220.00 -8.42%
-
DIVISLABDivi's Laboratories ₹11,080.00 -3.16%
-
MAXHEALTHMax Healthcare Institute ₹1,009.90 +6.63%
-
APOLLOHOSPApollo Hospitals Enterprise ₹8,771.00 +2.87%
-
AUROPHARMAAurobindo Pharma ₹1,794.00 -1.60%
-
PPLPHARMAPiramal Pharma ₹244.93 +0.16%
-
FORTISFortis Healthcare ₹803.20 +5.13%
-
SUNPHARMASun Pharmaceutical Industries ₹1,867.50 -0.66%
Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.